Dernières nouvelles pour Hanryu Holdings (NASDAQ:HRYU) Stock

Hanryu Holdings

Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.

Hanryu Holdings Inc

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

Equities

News

Markets

Movers

General

HALO

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Craig-Hallum analyst Richard Shannon maintains POET Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) with a Buy and raises the price target from $3.5 to $5.5.

Price Target

Analyst Ratings

POET

Craig-Hallum Maintains Buy on POET Technologies, Raises Price Target to $5.5

Janney Montgomery Scott analyst Christopher Marinac upgrades National Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKSH#NASDAQ">NKSH</a>) from Neutral to Buy and announces $38 price target.

Upgrades

NKSH

Janney Montgomery Scott Upgrades National Bankshares to Buy, Announces $38 Price Target

Craig-Hallum analyst Matthew Hewitt maintains Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) with a Buy and raises the price target from $8 to $10.

LFCR

Craig-Hallum Maintains Buy on Lifecore Biomedical, Raises Price Target to $10

Craig-Hallum analyst Jeff Van Rhee maintains Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) with a Hold and raises the price target from $3.5 to $6.

CRNC

Craig-Hallum Maintains Hold on Cerence, Raises Price Target to $6

DA Davidson analyst Peter Heckmann initiates coverage on CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy rating and announces Price Target of $36.

Initiation

PMTS

DA Davidson Initiates Coverage On CPI Card with Buy Rating, Announces Price Target of $36

Barrington Research analyst Gary Prestopino maintains PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) with a Outperform and raises the price target from $10 to $15.

AIOT

Barrington Research Maintains Outperform on PowerFleet, Raises Price Target to $15

RBC Capital analyst Scott Hanold maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Outperform and raises the price target from $102 to $116.

RBC Capital Maintains Outperform on Expand Energy, Raises Price Target to $116

IPOs

Trading Ideas

Ming Shing Group Shares Open For Trade At $5.65/Share; IPO Priced At $5.50/Share On 1.5M Shares

Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) with a Buy and raises the price target from $5 to $6.

WALD

Canaccord Genuity Maintains Buy on Waldencast, Raises Price Target to $6

Macro Economic Events

Economics

Biden Administration Approves New York Plan To Launch $9 Congestion Fee Starting Jan. 5

RBC Capital analyst Rishi Jaluria reiterates Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Outperform and maintains $760 price target.

Reiteration

INTU

RBC Capital Reiterates Outperform on Intuit, Maintains $760 Price Target

During the last three months, 4 analysts shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $87.25, with a high estimate of $100.00 and a low estimate of $76.00. Experiencing a 3.59% decline, the current average is now lower than the previous average price target of $90.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294863_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Keros Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$76.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Keros Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Keros Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KROS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Keros Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Keros Therapeutics</h2>
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
<h3>Financial Insights: Keros Therapeutics</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Keros Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4750.0% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Keros Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -13648.45%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Keros Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -10.24%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Keros Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KROS

Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

ICF International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICFI#NASDAQ">ICFI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.75, a high estimate of $185.00, and a low estimate of $140.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $169.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294854_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive ICF International. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$140.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Marc Riddick</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$180.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Kevin Steinke</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$174.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ICF International. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICF International compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for ICF International's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICF International's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICFI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICF International analyst ratings.</a>
<h2>All You Need to Know About ICF International</h2>
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian &amp; Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in single segment, which is providing professional services.
<h3>Key Indicators: ICF International's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, ICF International showcased positive performance, achieving a revenue growth rate of 3.09% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: ICF International's net margin excels beyond industry benchmarks, reaching 6.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ICF International's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.4%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): ICF International's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.62%, the company may face hurdles in achieving optimal financial performance.
Debt Management: ICF International's debt-to-equity ratio is below the industry average at 0.63, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ICFI

Expert Outlook: ICF International Through The Eyes Of 4 Analysts

Across the recent three months, 5 analysts have shared their insights on Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $117.6, along with a high estimate of $125.00 and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 4.44% from the previous average price target of $112.60.
<img src="https://www.benzinga.com/files/images/story/2024/1732294842_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Parsons by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobey Sommer</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Brian Gesuale</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$99.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Parsons. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Parsons compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Parsons's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Parsons's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PSN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Parsons analyst ratings.</a>
<h2>Delving into Parsons's Background</h2>
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe.
<h3>Parsons's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Parsons showcased positive performance, achieving a revenue growth rate of 27.6% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.97%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Parsons's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.18%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.35%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.6, Parsons adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 5 Analyst Ratings For Parsons

Canaccord Genuity analyst David Hynes maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Buy and raises the price target from $67 to $83.

PCOR

Canaccord Genuity Maintains Buy on Procore Technologies, Raises Price Target to $83

Ratings for USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $25.4, with a high estimate of $27.00 and a low estimate of $23.00. A 2.31% drop is evident in the current average compared to the previous average price target of $26.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294834_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive USA Compression Partners. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Douglas Irwin</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to USA Compression Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of USA Compression Partners compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of USA Compression Partners's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/USAC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on USA Compression Partners analyst ratings.</a>
<h2>Discovering USA Compression Partners: A Closer Look</h2>
USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services in several shale plays throughout the U.S., including the Utica, Marcellus, Permian Basin, Delaware Basin, Eagle Ford, and others.
<h3>Key Indicators: USA Compression Partners's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, USA Compression Partners showcased positive performance, achieving a revenue growth rate of 10.54% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 17.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.53%, the company showcases effective utilization of assets.
Debt Management: USA Compression Partners's debt-to-equity ratio surpasses industry norms, standing at 41.35. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

USAC

Decoding 5 Analyst Evaluations For USA Compression Partners

ASGN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $99.75, a high estimate of $115.00, and a low estimate of $88.00. Highlighting a 0.25% decrease, the current average has fallen from the previous average price target of $100.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732294826_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of ASGN among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$96.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Surinder Thind</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$88.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ASGN. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ASGN compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ASGN's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ASGN's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ASGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ASGN analyst ratings.</a>
<h2>Unveiling the Story Behind ASGN</h2>
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
<h3>Financial Insights: ASGN</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: ASGN's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -7.68%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: ASGN's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 4.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ASGN's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.65%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): ASGN's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: ASGN's debt-to-equity ratio is below the industry average. With a ratio of 0.62, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASGN

Navigating 4 Analyst Ratings For ASGN

Dick's Sporting Goods's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) short percent of float has fallen 5.99% since its last report. The company recently reported that it has 3.86 million shares sold short, which is 9.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dick's Sporting Goods Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732294825_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dick's Sporting Goods has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dick's Sporting Goods's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dick's Sporting Goods's peer group average for short interest as a percentage of float is 12.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Dick's Sporting Goods's Recent Short Interest

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 40.51% since its last report. The company recently reported that it has 7.67 million shares sold short, which is 5.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732294819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 5.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

TNXP

Looking Into Tonix Pharmaceuticals's Recent Short Interest

MSGM, CXDO among major communication services gainers; MNY, GAIA among losers

IMVT, FREY and LGMK among pre-market losers

NCTY, DRCT among major communication services gainers; ANGH, AMCX among losers

IPO Roundup: Amer Sports, FibroBiologics, and more

In 2023, there were 154 IPOs on the U.S. stock market. Here is a brief look at some of the worst-performing initial public offerings from last year.

The Worst-Performing U.S. IPOs Of 2023

Hanryu Holdings, Inc. (HRYU) has released an update. Hanryu Holdings, Inc. has been notified by Nasdaq that its stock price has fallen below the $1...

Hanryu Holdings Faces Nasdaq Delisting Over Low Stock Price

Hanryu Holdings, Inc. (HRYU) has provided an update. Hanryu Holdings, Inc. is in the midst of executive turmoil as TaeHoon Kim, the Chief Technolog...

Hanryu Holdings Faces Executive Leadership Dispute

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Tuesday morning!



<a href="https://investorplace.com/stock-types/meme-stocks/">Meme stocks</a> continue to rally, companies release earnings reports, and more market news has shares moving today.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>AMC Entertainment (NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>) stock is rocketing more than 59% as <a href="https://twitter.com/TheRoaringKitty">Roaring Kitty&rsquo;s return</a> continues to bolster the shares.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) shares are soaring over 54% alongside the return of Roaring Kitty.</li>



<li>MicroCloud Hologram (NASDAQ:<a href="https://investorplace.com/stock-quotes/holo-stock-quote/">HOLO</a>) stock is surging 41% with heavy pre-market trading.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are gaining more than 34% with strong early morning trading today.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is increasing over 27% without any clear news this morning.</li>



<li>BlackBerry (NYSE:<a href="https://investorplace.com/stock-quotes/bb-stock-quote/">BB</a>) shares are rising more than 24% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318312931&amp;type=PDF&amp;symbol=BB&amp;cdn=4b26c072318efaefdc3ba22b7b5e8deb&amp;companyName=BlackBerry+Limited&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2024-05-13">shareholder meeting update</a>.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is climbing over 19% this morning.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) shares are heading more than 19% higher <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314743&amp;type=PDF&amp;symbol=SPWR&amp;cdn=ecf4fe81973e2491082785bf9c740edb&amp;companyName=SunPower+Corporation&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">despite a delayed filing</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is jumping over 18% on Tuesday morning.</li>



<li>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) shares are up more than 16% <a href="https://investorplace.com/2024/05/blast-from-the-past-former-meme-koss-stock-soars-on-roaring-kitty-news/">alongside the meme stock rally</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Inotiv (NASDAQ:<a href="https://investorplace.com/stock-quotes/notv-stock-quote/">NOTV</a>) stock is plummeting over 34% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314218&amp;type=PDF&amp;symbol=NOTV&amp;cdn=ebe87b345e7637122dc6a4d631ded890&amp;companyName=Inotiv+Inc.&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">alongside preliminary earnings</a>.</li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving close to 33% after releasing its <a href="https://www.nasdaq.com/press-release/augmedix-delivers-40-revenue-growth-for-first-quarter-of-2024-2024-05-13">latest earnings report</a>.</li>



<li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock is tumbling more than 22% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318315844&amp;type=PDF&amp;symbol=SCPX&amp;cdn=2f4148150720f83231bf9f50680f426c&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-05-13">with a public offering</a>.</li>



<li>Akoya Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/akya-stock-quote/">AKYA</a>) shares are taking an over 19% beating after <a href="https://www.marketwatch.com/story/shares-of-akoya-biosciences-drop-after-1q-earnings-revenue-outlook-miss-c9dded98?mod=newsviewer_click">missing Q1 estimates</a>.</li>



<li>Eastside Distilling (NASDAQ:<a href="https://investorplace.com/stock-quotes/east-stock-quote/">EAST</a>) stock is dropping more than 18% after <a href="https://www.nasdaq.com/press-release/eastside-distilling-reports-first-quarter-2024-financial-results-2024-05-13">posting its Q1 results</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are sliding over 14% this morning.</li>



<li>Terran Orbital (NYSE:<a href="https://investorplace.com/stock-quotes/llap-stock-quote/">LLAP</a>) stock is falling more than 14% with its <a href="https://www.businesswire.com/news/home/20240514904938/en/Terran-Orbital-Reports-First-Quarter-2024-Financial-Results">Q1 earnings report</a>.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) shares are slipping over 13% this morning.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dipping more than 12% today.</li>



<li>Intelligent Living (NASDAQ:<a href="https://investorplace.com/stock-quotes/ilag-stock-quote/">ILAG</a>) shares close out our pre-market stock movers down over 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-may-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Hanryu Holdings received notice of non-compliance from Nasdaq

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!



Moving stocks this morning are patent news, a new investment, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Syntec Optics (NASDAQ:<a href="https://investorplace.com/stock-quotes/optx-stock-quote/">OPTX</a>) stock is rocketing more than 248% alongside heavy pre-market trading.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 75% after <a href="https://www.nasdaq.com/press-release/anew-medical-inc-secures-key-patent-europe-human-klotho-gene-rna-slice-variant-and">securing a key patent in Europe</a>.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is surging more than 36% as it <a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">continues yesterday&rsquo;s rally</a>.</li>



<li>Rivian Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>) shares are gaining over 36% on a <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html">$5 billion investment</a>.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) stock is increasing more than 32% with strong trading this morning.</li>



<li>Savara (NASDAQ:<a href="https://investorplace.com/stock-quotes/svra-stock-quote/">SVRA</a>) shares are rising over 26% on a <a href="https://seekingalpha.com/news/4119362-savara-stock-surges-trial-win-lead-asset?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">positive clinical trial</a>.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is heading more than 21% higher on Wednesday morning.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are climbing over 18% even as it plans to <a href="https://finance.yahoo.com/news/effector-therapeutics-announces-wind-down-110000717.html">wind down operations</a>.</li>



<li>Golden Matrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmgi-stock-quote/">GMGI</a>) stock is jumping more than 15% today.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are up over 14% <a href="https://investorplace.com/2024/06/faraday-future-stock-shocker-from-ev-maker-to-china-u-s-auto-middleman/">on survival plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NextTrip (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntrp-stock-quote/">NTRP</a>) stock is diving more than 24% without any recent news to report.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares are tumbling over 15% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318415310&amp;type=PDF&amp;symbol=GRI&amp;cdn=40db9b65c5660c095bf51f08f72c725f&amp;companyName=GRI+Bio+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-26">proposed public offering</a>.</li>



<li>Taysha Gene Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsha-stock-quote/">TSHA</a>) stock is taking a 14% beating on <a href="https://www.nasdaq.com/press-release/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-funded">public offering plans</a>.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares are sliding more than 12% despite a lack of news this morning.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) stock is decreasing over 11% on Wednesday.</li>



<li>Hamilton Beach Brands (NYSE:<a href="https://investorplace.com/stock-quotes/hbb-stock-quote/">HBB</a>) shares are dropping more than 10% today.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is falling over 10% <a href="https://finance.yahoo.com/news/senior-vp-chief-medical-officer-100744620.html">despite insider buying</a>.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) shares are slipping more than 9% today.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is dipping over 9% this morning.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares close out our pre-market stock movers down more than 9% as they <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">prepare for delisting tomorrow</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

AKYA

ALDX

AMCX

ANGH

AREN

ARGX

ATAK

ATNI

AUGX

BAOS

BHVN

BLUE

BMRA

BTSG

BVFL

CGON

CHNR

CTNT

CXDO

DGLY

DMTK

DOCO

DRCT

EAST

EFTR

ENSC

FBLG

FFIE

FREY

GAIA

GLYC

GMGI

GOVX

HOLO

HRYU

ICCT

ILAG

IMVT

INTJ

INVO

KOSS

LGCB

LGMK

LLAP

LSDI

MGRX

MIRA

MSGM

NCTY

NOTV

NTRP

NUZE

OBLG

OPTX

PBLA

PMNT

PXDT

RENT

RIVN

ROIV

SCHL

SCPX

SFWL

SPWR

SRFM

SUBL

SVRA

TLPH

TSHA

TZOO

UCAR

VLCN

WENA

WRNT

XNET

ZDGE

ZJYL

Small Cap

Opinion

Press Releases

Thinking about buying stock in Processa Pharmaceuticals, Adobe Inc, Progressive Corp, Hanryu Holdings, or Esperion Therapeutics?

Thinking about buying stock in Compugen, Hanryu Holdings, Super Micro Computer, Coterra Energy, or Applied Therapeutics?

Hanryu Holdings, Inc. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

Legal

ADBE

APLT

CGEN

CTRA

ESPR

PCSA

SMCI

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

Hanryu Holdings

Actualités

Dernières nouvelles pour Hanryu Holdings (NASDAQ:HRYU) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL